-
公开(公告)号：AU2011237601B2
公开(公告)日：2015-08-20
申请号：AU2011237601
申请日：2011-04-07
Applicant: VERTEX PHARMA
Inventor： VERWIJS MARINUS JACOBUS , ALARGOVA ROSSITZA GUEORGUIEVA , KAUSHIK RITU ROHIT , KADIYALA IRINA NIKOLAEVNA , YOUNG CHRISTOPHER RYAN
IPC: A61K9/20
Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2- difluorobenzo [d] [ 1,3 ] dioxol-5 -y1) cyclopropanecarboxamido)-3 -methylpyridin-2-y1)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
-
公开(公告)号：AU2015205839A1
公开(公告)日：2015-08-13
申请号：AU2015205839
申请日：2015-07-21
Applicant: VERTEX PHARMA
Inventor： VERWIJS MARINUS JACOBUS , ALARGOVA ROSSITZA GUEORGUIEVA , KAUSHIK RITU ROHIT , KADIYALA IRINA NIKOLAEVNA , YOUNG CHRISTOPHER RYAN
IPC: A61K9/20
Abstract: PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2 DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3 METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF Abstract A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2 difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2 yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
-
公开(公告)号：NZ603043A
公开(公告)日：2015-02-27
申请号：NZ60304311
申请日：2011-04-22
Applicant: VERTEX PHARMA
Inventor： SHETH URVI JAGDISHBHAI , BOTFIELD MARTYN CURTIS , ALCACIO TIM EDWARD , YANG XIAOQING , SULLIVAN MARK JEFFREY , HURLEY DENNIS JAMES , AREKAR SNEHA G , KESHAVARZ-SHOKRI ALI , ZHANG BEILI , ZLOKARNIK GREGOR , KRAWIEC MARIUSZ , ALARGOVA ROSSITZA GUEORGUIEVA , ZHANG YUEGANG , BINCH HAYLEY MARIE , FANNING LEV TYLER DEWEY , JOHNSTON STEVEN C , YOUNG CHRISTOPHER RYAN , NUMA MEHDI , SILINA ALINA , GROOTENHUIS PETER DIEDERIK JAN , VAN GOOR FREDRICK F , ZAMAN NOREEN TASNEEM , MUDUNURI PRAVEEN , KAUSHIK RITU ROHIT , MEDEK ALES , KADIYALA IRINA NIKOLAEVNA , LEE ELAINE CHUNGMIN , LUISI BRIAN , VERWIJS MARINUS JACOBUS
IPC: A61K31/443 , A61K31/36 , A61K31/47 , C07D213/75 , C07D215/233 , C07D215/56 , C07D317/46
Abstract: Disclosed is a pharmaceutical composition comprising: Compound 1 SDD Formulation and Compound 3 Form I Tablet Formulation wherein: Compound 1 SDD Formulation is a spray dried dispersion of ivacaftor (VX-770), which comprises from about 45 wt% to about 85 wt% of substantially amorphous ivacaftor by weight of the dispersion, from about 14.45 wt% to about 55.55 wt% of hydroxypropylmethylcellulose acetate succinate (HPMCAS) by weight of the dispersion, and from about 0.45 wt% to about 0.55 wt% sodium lauryl sulfate (SLS) by weight of the dispersion; Compound 3 Form I Tablet Formulation comprises: crystalline form I of lumacaftor (VX-809) (characterized by one or more peaks at 15.2 to 15.6 degrees, 16.1 to 16.5 degrees, and 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation) in an amount ranging from about 20 wt% to about 80 wt% by weight of the composition; a filler comprising microcrystalline cellulose in an amount ranging from about 20 wt% to about 50 wt% by weight of the composition; a disintegrant comprising sodium croscarmellose sodium in an amount ranging from about 1 wt% to about 5 wt% by weight of the composition; a surfactant comprising sodium lauryl sulfate in an amount ranging from about 2 wt% to about 0.3 wt% by weight of the composition; a diluent comprising mannitol in an amount ranging from about 1 wt% to about 30 wt% by weight of the composition; a lubricant comprising magnesium stearate in an amount ranging from about 0.3 wt% to about 5 wt% by weight of the composition; and at least one of: a binder comprising polyvinylpyrrolidone in an amount ranging from about 0.1 wt% to about 5 wt% by weight of the composition and a glidant comprising colloidal silica in an amount ranging from about 0.05 wt% to about 2 wt% by weight of the composition. Also disclosed is the use of the pharmaceutical composition as defined above in the manufacture of a medicament for treating a CFTR mediated disease in a human, wherein the CFTR mediated disease is selected from cystic fibrosis, COPD, emphysema, dry-eye disease or osteoporosis.
-
公开(公告)号：NZ597823A
公开(公告)日：2014-05-30
申请号：NZ59782310
申请日：2010-02-18
Applicant: VERTEX PHARMA
Inventor： ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER R , DINEHART KIRK , VERWIJS MARINUS JACOBUS , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO , ZLOKARNIK GREGOR , VAN GOOR FREDRICK F
Abstract: 597823 Disclosed herein are pharmaceutical compositions comprising a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) for use treating or lessening the severity of cystic fibrosis in a patient, and method of manufacturing said compositions. In a preferred embodiment the patient possesses a cystic fibrosis transmembrane receptor (CFTR) with a &Dgr;F508 mutation or G551D mutation on both alleles.
-
公开(公告)号：HK1161140A1
公开(公告)日：2012-08-24
申请号：HK12102076
申请日：2012-02-29
Applicant: VERTEX PHARMA
Inventor： ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER , DINEHART KIRK , VERWIJS MARINUS JACOBUS , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO
IPC: A61K20060101
Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
-
Patent Agency Ranking
公开(公告)号：CA2769695A1
公开(公告)日：2011-02-17
申请号：CA2769695
申请日：2010-02-18
Applicant: VERTEX PHARMA
Inventor： ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER R , DINEHART KIRK , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO , ZLOKARNIK GREGOR , VAN GOOR FREDRICK F , VERWIJS MARINUS JACOBUS
Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
-
公开(公告)号：SMT202500078T1
公开(公告)日：2025-03-12
申请号：SMT202500078
申请日：2013-11-01
Applicant: VERTEX PHARMA
Inventor： VERWIJS MARINUS JACOBUS , KARKARE RADHIKA , MOORE MICHAEL DOUGLAS
-
公开(公告)号：MX379946B
公开(公告)日：2025-03-11
申请号：MX2018014775
申请日：2012-10-05
Applicant: VERTEX PHARMA
Inventor： YOUNG CHRISTOPHER RYAN , KADIYALA IRINA NIKOLAEVNA , VERWIJS MARINUS JACOBUS , KAUSHIK RITU ROHIT , ALARGOVA ROSSITZA GUEORGUIEVA
IPC: A61K31/443 , A61K9/16 , A61K9/20 , A61K9/28 , C07D213/75 , C07D405/12 , C07D405/14
Abstract: Una composición farmacéutica que comprende el Compuesto 1, ácido (3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico), y al menos un excipiente seleccionado de: un relleno, un diluyente, un disgregante, un agente tensioactivo, un aglutinante, un deslizante y un lubricante, la composición siendo adecuada para administración oral a una paciente en la necesidad de esto para tratar una enfermedad mediada por CFTR tal como Fibrosis Cística. Métodos para tratar un paciente en a necesidad de esto incluyen la administración de una formulación farmacéutica oral del Compuesto 1 al paciente.
-
公开(公告)号：DK3470063T3
公开(公告)日：2025-01-20
申请号：DK18192504
申请日：2013-11-01
Applicant: VERTEX PHARMA
Inventor： VERWIJS MARINUS JACOBUS , KARKARE RADHIKA , MOORE MICHAEL DOUGLAS
IPC: A61P11/00 , A61K9/20 , A61K31/443 , A61K31/47 , A61K45/06
-
公开(公告)号：SI3150198T1
公开(公告)日：2021-11-30
申请号：SI201132009
申请日：2011-04-07
Applicant: VERTEX PHARMA
Inventor： VERWIJS MARINUS JACOBUS , ALARGOVA ROSSITZA GUEORGUIEVA , KAUSHIK RITU ROHIT , KADIYALA IRINA NIKOLAEVNA , YOUNG CHRISTOPHER RYAN
IPC: A61K9/00 , C07D213/00 , C07D405/00
-
-
-
-
-
-
-
-
-
Search Results
98
records
(took 0.023 seconds)
